Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

ketamine

Science

13 Oct 2023

FDA Issues Warning Letter for Ketamine

The FDA has issued a warning letter regarding the use of ketamine outside of FDA-approved conditions....

By Jason Najum
mushroom rats

Science

11 Oct 2023

New Study Shows Microdoses Reduce Compulsive Behavior (in rats)

A new study in rodents shows that low doses of psilocybin increase resilience to stress and lower compulsive actions....

By Jason Najum

Breaking News, Law & Politics

8 Oct 2023

Breaking News: California Governor Vetoes Psychedelics Decriminalization Bill

California governor has vetoed a major psychedelic decrim bill, but supports a comprehensive law that establishes guidelines for regulated therapeutic access....

By Jason Najum

Science

6 Oct 2023

New Study Shows Spravato Effective When Combined With SSRIs

A new study published in the New England Journal of Medicine found that Spravato’s esketamine was more effective than a commonly prescribed drug in treating treatment-resistant depression....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

29 Sep 2023

Canadian Military Veteran Receives Approval for Psilocybin Therapy

Health Canada has granted permission for a Canadian military veteran to receive much-needed psilocybin therapy....

By Jason Najum
pills

Science

26 Sep 2023

Positive Data from Small Pharma’s New Study Combining DMT & SSRIs

Topline results from Small Pharma's Phase Ib study exploring the interaction between SSRIs and SPL026, the company’s DMT drug....

By Jason Najum

Finance

18 Sep 2023

Billionaire Investor Steve Cohen Buys 19 million Shares of Cybin

Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin....

By Jason Najum
ketamine

Breaking News

6 Sep 2023

PharmaTher Submits New Drug Application to the FDA

Will PharmaTher be the next company to get a psychedelic medicine to market?...

By Jason Najum
mushrooms

Science

31 Aug 2023

New Johns Hopkins Study Shows Psilocybin Helps Long Term Mental Health

A new study from Johns Hopkins shows that psilocybin use promotes positive long-term effects on well-being....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.